
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 09, 2023, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.".
Filed with NSE ·

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 09, 2023, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.".
6ix hasn’t read this filing yet.
Alembic Pharmaceuticals Limited on 6ix
Follow Alembic Pharmaceuticals into a list and get an email when it puts out news.
Follow Alembic Pharmaceuticals